A pragmatic approach to the design of population pharmacokinetic studies
- PMID: 16353920
- PMCID: PMC2750978
- DOI: 10.1208/aapsj070241
A pragmatic approach to the design of population pharmacokinetic studies
Abstract
The publication of a seminal article on nonlinear mixed-effect modeling led to a revolution in pharmacokinetics (PKs) with the introduction of the population approach. Since then, interest in obtaining accurate and precise estimates of population PK parameters has led to work on population PK study design that extended previous work on optimal sampling designs for individual PK parameter estimation. The issues and developments in the design of population PK studies are reviewed as a prelude to investigating, via simulation, the performance of 2 approaches (population Fisher information matrix D-optimal design and informative block [profile] randomized [IBR] design) for designing population PK studies. The results of our simulation study indicate that the designs based on the 2 approaches yielded efficient parameter estimates. The designs based on the 2 approaches performed similarly, and in some cases designs based on the IBR approach were slightly better. The ease with which the IBR designs can be generated makes them preferable in drug development, where pragmatism and time are of great consideration. We, therefore, refer to the IBR designs as pragmatic designs. Pragmatic designs that achieve high efficiency in the estimation parameters should be used in the design of population PK studies, and simulation should be used to determine the efficiency of the designs.
Similar articles
-
An evaluation of population D-optimal designs via pharmacokinetic simulations.Ann Biomed Eng. 2003 Jan;31(1):98-111. doi: 10.1114/1.1533074. Ann Biomed Eng. 2003. PMID: 12572660
-
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.Stat Med. 2002 Sep 30;21(18):2623-39. doi: 10.1002/sim.1041. Stat Med. 2002. PMID: 12228881
-
An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.J Biopharm Stat. 2009;19(1):174-89. doi: 10.1080/10543400802536131. J Biopharm Stat. 2009. PMID: 19127474
-
Pharmacodynamic parameter estimation: population size versus number of samples.AAPS J. 2005 Oct 5;7(2):46. doi: 10.1208/aapsj070246. AAPS J. 2005. PMID: 16353905 Free PMC article. Review.
-
Design of population pharmacokinetic experiments using prior information.Xenobiotica. 2007 Oct-Nov;37(10-11):1311-30. doi: 10.1080/00498250701553315. Xenobiotica. 2007. PMID: 17968747 Review.
Cited by
-
Population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin after intravenous injection to cats with reduced kidney function.J Vet Intern Med. 2023 Nov-Dec;37(6):2230-2240. doi: 10.1111/jvim.16866. Epub 2023 Sep 20. J Vet Intern Med. 2023. PMID: 37728198 Free PMC article.
-
Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial.BMJ Open. 2025 Jun 8;15(6):e096523. doi: 10.1136/bmjopen-2024-096523. BMJ Open. 2025. PMID: 40484425 Free PMC article.
-
Random sparse sampling strategy using stochastic simulation and estimation for a population pharmacokinetic study.Saudi Pharm J. 2014 Jan;22(1):63-9. doi: 10.1016/j.jsps.2013.01.010. Epub 2013 Feb 10. Saudi Pharm J. 2014. PMID: 24493975 Free PMC article.
-
Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.Pharm Res. 2009 Oct;26(10):2259-69. doi: 10.1007/s11095-009-9942-y. Epub 2009 Aug 11. Pharm Res. 2009. PMID: 19669867 Free PMC article.
-
Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.Paediatr Drugs. 2009;11(1):33-7. doi: 10.2165/0148581-200911010-00012. Paediatr Drugs. 2009. PMID: 19127950 Review.
References
-
- Beal SL, Sheiner LB. Estimating population pharmacokinetics. Crit Rev Biomed Eng. 1982;8:195–222. - PubMed
-
- Guidance for Industry: Population Pharmacokinetics. Washington, DC: United States Food and Drug Administration; 1999.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous